Gazyva (obinutuzumab (rch)) in combination with chemotherapy followed by Gazyva maintenance is now indicated for the treatment of previously untreated advanced follicular lymphoma.
Xalkori (crizotinib) is now indicated for the treatment of ROS1 positive advanced non-small cell lung cancer.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629